Alison Moore
Director/Board Member bei CODEXIS, INC.
Vermögen: 3 Mio $ am 31.03.2024
Profil
Zurzeit bekleidet Alison Moore die Position des Chief Technical Officer bei Allogene Therapeutics, Inc. Dr. Moore ist auch im Vorstand von Codexis, Inc. In der Vergangenheit hatte Dr. Moore die Position des Senior Vice President-Process Development bei Amgen, Inc. und Director-Chemistry, Manufacturing & Controls bei Genentech, Inc. inne. Alison Moore erhielt einen Doktortitel und einen Bachelor-Abschluss von der University of Manchester.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
22.03.2023 | 670 173 ( 0,40% ) | 3 Mio $ | 31.03.2024 | |
CODEXIS, INC.
0,10% | 13.06.2023 | 68 576 ( 0,10% ) | 239 330 $ | 31.03.2024 |
Aktive Positionen von Alison Moore
Unternehmen | Position | Beginn |
---|---|---|
CODEXIS, INC. | Director/Board Member | 16.06.2020 |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Director/Board Member | - |
Ehemalige bekannte Positionen von Alison Moore
Unternehmen | Position | Ende |
---|---|---|
ALLOGENE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 28.04.2023 |
AMGEN INC. | Corporate Officer/Principal | 01.06.2018 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | General Counsel | 01.01.2006 |
Ausbildung von Alison Moore
The University of Manchester | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
AMGEN INC. | Health Technology |
CODEXIS, INC. | Process Industries |
ALLOGENE THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |